APA RP Patient Summary
A Study of an Investigational Medicine and Androgen Deprivation Therapy (standard of care) in Participants Who Have Undergone Prostate Removal Surgery for their Prostate Cancer and Are at High Risk for Metastases
WHO IS THIS STUDY MEANT FOR?
This study is looking for men with prostate cancer at high risk of metastasis* and who have recently undergone or are planning to undergone radical prostatectomy (RP) surgery.
*Metastasis – involves the spread of cancer to other parts of the body from the place it first formed
*Radical prostatectomy – surgery involving the removal of the prostate gland
WHY IS THIS CLINICAL RESEARCH STUDY BEING DONE?
The purpose of this study is to evaluate an investigational medicine in combination with Androgen Deprivation Therapy (ADT), the standard of care, for the prevention of a type of recurrence and progression of prostate cancer after RP surgery.
Often, men with high-risk localized prostate cancer undergo radical prostatectomy, which may cure prostate cancer in men whose cancer is contained within the prostate. However, in some high-risk patients, the disease may recur.
All patients in this study will get the investigational medication every day after the RP surgery as directed by your doctor. All patients in this study will also get ADT after the RP surgery.
Your study doctor will be able to explain to you about the study-related visits and what is required of you if you are eligible to participate in this study.
Who can participate?
You may be able to participate in this study if you:
There are other qualifying criteria that your study doctor will be able to discuss with you in more detail.
Interested in participation?
To learn more about this study, if you may be eligible and if the study is being conducted at a site near you, please visit: Clinicaltrials.gov or Janssen Clinical Trial Finder\APA2041
To learn more about clinical trials, please visit: About Clinical Trials\Janssen Clinical Trial Finder
Organization: Janssen Research & Development, LLC
If you are interested in this trial, review the following:
PHEN Contact: 617-481-4020
PHEN,Inc. © 2023 All rights reserved